Search results
Results from the WOW.Com Content Network
Though EBNA1 is a well-characterized protein, its role in oncogenesis is less well defined. It is consistently expressed in EBV-associated tumors. [1] EBNA1 is the only identified latent protein-encoding genes that it consistently expressed in Burkitt's lymphoma cells [6] and is believed to contribute to EBV malignancies through B cell-directed expression.
In 2009, a case-control study of 187 triple-negative breast cancer patients described a 2.5 increased risk for triple-negative breast cancer in women who used oral contraceptives (OCs) for more than one year, compared to women who used OCs for less than one year or never. [12] The increased risk for triple-negative breast cancer was 4.2 among ...
Epstein–Barr virus–associated lymphoproliferative diseases (also abbreviated EBV-associated lymphoproliferative diseases or EBV+ LPD) are a group of disorders in which one or more types of lymphoid cells (a type of white blood cell), i.e. B cells, T cells, NK cells, and histiocytic-dendritic cells, are infected with the Epstein–Barr virus (EBV).
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
The Triple Negative Breast Cancer Foundation ("TNBC Foundation") is a nonprofit organization dedicated to raising awareness of triple negative breast cancer.The foundation supports scientists and researchers in their efforts to determine the definitive causes of triple negative breast cancer so that effective detection, diagnosis, prevention, and treatment can be pursued and achieved.
Staging of breast cancer is one aspect of breast cancer classification that assists in making appropriate treatment choices, when considered along with other classification aspects such as estrogen receptor and progesterone receptor levels in the cancer tissue, the human epidermal growth factor receptor 2 status, menopausal status, and the ...
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
The A4 study on older individuals who are positive for indicators of AD but are negative for genetic risk factors will test Solanezumab in Phase III Clinical Trials, as a follow-up of previous Solanezumab studies. [26] DIAN-TU, launched in December 2012, focuses on young patients positive for genetic mutations that are risks for AD.